
1. J Antimicrob Chemother. 2021 Feb 20. pii: dkab027. doi: 10.1093/jac/dkab027.
[Epub ahead of print]

Legionella antibiotic susceptibility testing: is it time for international
standardization and evidence-based guidance?

Portal E(1)(2), Descours G(3), Ginevra C(3), Mentasti M(4), Afshar B(2), Chand
M(2), Day J(2), Echahidi F(5), Franzin L(6), Gaia V(7), Lück C(8), Meghraoui
A(9), Moran-Gilad J(10), Ricci ML(11), Lina G(3), Uldum S(12), Winchell J(13),
Howe R(4), Bernard K(14), Spiller OB(1), Chalker VJ(2)(15), Jarraud S(3), Ahlen
C, Hashmi IA, Allestam G, Amemura-Maekawa J, Andersson S, Bangsborg JM, Bararossa
S, Beraud L, Bernard K, Borella P, Brandsema P, Bruin JP, Buzzigoli A, Cano R,
Casini B, Celenza G, Chalker V, Collins S, Rotger SC, Cristina ML, Cristino S,
David S, Jong B, Boer JD, Echahidi F, Elverdal PL, Erdogan H, Euser S, Franzin L,
Fry NK, Gaia V, Garcia-Nuñez M, Ginevra C, Pasmal de Ameida Concalves EF,
Gonçalves P, Fernandez TG, Grottola A, Gysin N, Harrison TG, Höfle M, Jarraud S, 
Jorgensen CS, Joseph C, Slott Kanto B, Kese D, Kindingstad L, Klingenberg DE,
Kösekul M, Kozak-Muiznieks N, Kura F, Kusnetsov J, Lai S, Lee S, Lee JV, Lindsay 
D, Lück C, Leuscher M, der Lugt WV, Marques MT, Meacci M, Meghraoui A, Mentasti
M, Mentula S, Mikrut A, Modol J, Moore G, Moran-Gilad J, Morin M, Otgun SN,
Nataas OB, Abadi NN, Pancer K, Pecorari M, Pedro-Botet ML, Pelaz C, Petzold M,
Pissarides N, Portal EAR, Ramliden M, Raphael B, Reddington K, Ricci ML, Robesyn 
E, Roisin S, Rumpianesi F, Saenz H, Scaturro M, Schalk J, Simone G, Bjerregaard
SS, Spagnolo AM, Spiller OB, Aspelund AS, Svarrer CW, Tartakovshiy I, Templeton
K, Uldum S, Veschetti E, Walker J, Wallet F, Wewalka G, Whapham C, Wunderlich A, 
Wybo I.

Author information: 
(1)Medical Microbiology, Department of Infection and Immunity, School of
Medicine, Cardiff University, Cardiff, UK.
(2)Bacteriology Reference Department, Public Health England, London, UK.
(3)Centre National de Reference des Legionelles, Hospices Civils de Lyon,
University de Lyon, Lyon, France.
(4)Public Health Wales, Cardiff, UK.
(5)Department of Microbiology and Infection Control, National Reference Centre
for Legionella pneumophila, Vrije Universiteit Brussel, Universitair Ziekenhuis
Brussel, Brussels, Belgium.
(6)Ospedale Amedeo di Savoia, Torino, Italy.
(7)Department of Laboratory Medicine, Reference Centre for Legionella,
Bellinzona, Switzerland.
(8)German Consiliary Laboratory for Legionella, Institute of Medical Microbiology
and Hygiene, Dresden University of Technology, Dresden, Germany.
(9)Department of Microbiology, National Reference Centre for Legionella
pneumophila, Laboratoire Hospitalier Universitaire de Bruxelles-University
Laboratory of Brussels (LHUB-ULB), Belgium.
(10)Department of Health Systems Management, Faculty of Health Sciences, Ben
Gurion University of the Negev, Beer Sheva, Israel.
(11)National Institute for Health, Rome, Italy.
(12)Statens Serum Institute, Copenhagen, Denmark.
(13)National Center for Immunization and Respiratory Diseases, Centres for
Disease Control and Prevention, Atlanta, GA, USA.
(14)Special Bacteriology Unit, National Microbiology Laboratory-PHAC, Winnipeg,
Canada.
(15)National Institute for Health Research Health Protection Research Unit (NIHR 
HPRU) in Respiratory Infections at Imperial College London in partnership with
Public Health England (PHE), London, UK.

Legionella pneumophila, a Gram-negative bacillus, is the causative agent of
Legionnaire's disease, a form of severe community-acquired pneumonia. Infection
can have high morbidity, with a high proportion of patients requiring ICU
admission, and up to 10% mortality, which is exacerbated by the lack of efficacy 
of typical empirical antibiotic therapy against Legionella spp. The fastidious
nature of the entire Legionellaceae family historically required inclusion of
activated charcoal in the solid medium to remove growth inhibitors, which
inherently interferes with accurate antimicrobial susceptibility determination,
an acknowledged methodological shortfall, now rectified by a new solid medium
that gives results comparable to those of microbroth dilution. Here, as an
international Legionella community (with authors representing various
international reference laboratories, countries and clinical stakeholders for
diagnosis and treatment of legionellosis), we set out recommendations for the
standardization of antimicrobial susceptibility testing methods, guidelines and
reference strains to facilitate an improved era of antibiotic resistance
determination.

© The Author(s) 2021. Published by Oxford University Press on behalf of the
British Society for Antimicrobial Chemotherapy. All rights reserved. For
permissions, please email: journals.permissions@oup.com.

DOI: 10.1093/jac/dkab027 
PMID: 33608737 

